Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18352511 | 1.00 | HDAC6 (0.35) | HDAC6CHRNB2CHRNA4TSHRHDAC1 | |
| SCHEMBL19149608 | 0.85 | HDAC6 (0.36) | HDAC6CHRNB2CHRNA4HDAC1HDAC2 | |
| SCHEMBL6418739 | 0.83 | HDAC6 (0.38) | HDAC6CHRNB2CHRNA4HDAC1HDAC2 | |
| SCHEMBL19149609 | 0.83 | AAK1 (0.33) | HDAC6CHRNB2CHRNA4HDAC1HDAC2 | |
| SCHEMBL6418732 | 0.83 | HDAC6 (0.38) | HDAC6CHRNB2CHRNA4HDAC1HDAC2 | |
| SCHEMBL18352677 | 0.81 | CHRNB2 (0.37) | CHRNB2CHRNA4TSHRCHRNB4CHRNA3 | |
| SCHEMBL18353131 | 0.81 | CHRNB2 (0.37) | CHRNB2CHRNA4TSHRCHRNB4CHRNA3 | |
| SCHEMBL18353130 | 0.80 | HCAR2 (0.40) | CHRNB2CHRNA4TSHRCHRNB4CHRNA3 | |
| SCHEMBL18353200 | 0.80 | HCAR2 (0.40) | CHRNB2CHRNA4TSHRCHRNB4CHRNA3 | |
| SCHEMBL18352514 | 0.80 | HCAR2 (0.44) | CHRNB2CHRNA4TSHRCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001952-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001952-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001952-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HDAC6 20/4885CHRNB2 2170/4885CHRNA4 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.